2 July 2025 - Apotex today announced that Health Canada has approved Aflivu (aflibercept), a biosimilar to Eylea, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular oedema secondary to central or branch retinal vein occlusion, treatment of diabetic macular oedema, and treatment of myopic choroidal neovascularisation.

This approval marks a key milestone for Apotex, introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016, and reflecting the Company's commitment to expand its biologics portfolio and execution of its Journey of Health strategy.

Read Apotex press release